<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Furr, Noah</style></author><author><style face="normal" font="default" size="100%">Ulmer, Ansley</style></author><author><style face="normal" font="default" size="100%">Cardon, Brock</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mullen, Rebecca</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Shoring Up Osteoporosis Management: A Fresh Start?</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of the American Board of Family
                Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">490-493</style></pages><doi><style  face="normal" font="default" size="100%">10.3122/jabfm.2024.240060R0</style></doi><volume><style face="normal" font="default" size="100%">37</style></volume><issue><style face="normal" font="default" size="100%">3</style></issue><abstract><style  face="normal" font="default" size="100%">Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.</style></abstract></record></records></xml>